Refractory Anemia: Causes, Symptoms, and Management

Refractory anemia is a form of anemia that does not improve with standard treatments like iron supplements or vitamins, and it belongs to a family of blood disorders called myelodysplastic syndromes, or MDS. The problem originates in the bone marrow, where blood-forming stem cells become defective and fail to produce healthy red blood cells in adequate numbers. Despite a marrow that is often packed with developing cells, those cells die prematurely before they ever reach the bloodstream, creating a puzzling mismatch between a busy factory floor and an empty output line. Understanding what drives this process, how it is classified, and what can be done about it matters because the condition ranges from a manageable chronic illness to a precursor of acute leukemia.

Why the Bone Marrow Fails

Refractory anemia stems from acquired damage to the stem cells that give rise to all blood cell lines. These damaged stem cells still divide and attempt to mature, so the marrow frequently looks hypercellular under a microscope. The paradox is that despite all this activity, mature red blood cells do not make it into circulation in normal numbers. This phenomenon, called ineffective hematopoiesis, is the central feature of MDS as a whole.¹

The main reason those developing cells fail is excessive programmed cell death. In healthy marrow, a small fraction of precursor cells undergo apoptosis as a normal quality-control step. In refractory anemia, this process goes into overdrive. Studies show that marrow cells from patients with the ring sideroblast subtype display significantly higher rates of spontaneous apoptosis and elevated activity of caspases, the enzymes that execute the cell-death program.² This excess apoptosis appears especially relevant in lower-risk forms of MDS, where it accounts for much of the gap between marrow cellularity and blood counts.³

The Role of Inflammation and the Marrow Environment

The bone marrow is not just a passive scaffold. It is an active immune environment, and chronic inflammation within it plays a surprisingly important role in driving refractory anemia. Sustained inflammatory signaling pushes stem cells out of their normal resting state, and over time this chronic stress impairs stem cell function, encourages mutations, and suppresses normal blood cell production.⁴

Aging amplifies this problem. Research in animal models has shown that damage-associated molecules accumulate in aging marrow and trigger resident immune cells to release inflammatory signals like TNF-alpha and IL-6. These cytokines directly inhibit red blood cell development and cause precursor cells to undergo apoptosis through oxidative stress and caspase activation.⁵ This helps explain why MDS is overwhelmingly a disease of older adults, with most diagnoses occurring after age 65.

Certain genetic mutations common in MDS further inflame this environment. Mutations in genes that regulate how immune cells resolve inflammation, or that activate an inflammatory complex called the NLRP3 inflammasome, create a vicious cycle: the mutant clone thrives while normal stem cells are suppressed.⁶

Genetic Mutations That Shape the Disease

Not all refractory anemia is the same, and much of what distinguishes one patient’s disease from another comes down to which genes are mutated. One of the most clinically meaningful discoveries in recent years involves the SF3B1 gene, which encodes part of the machinery cells use to process genetic instructions. Mutations in SF3B1 are found at strikingly high rates in patients whose marrow contains ring sideroblasts, which are red blood cell precursors with abnormal iron deposits encircling the nucleus. In one large study of nearly 300 patients with myeloid neoplasms and ring sideroblasts, SF3B1 mutations were detected in about 81% of those with the ring sideroblast subtypes of MDS.⁷ A separate study found SF3B1 mutations in roughly 65% of MDS patients whose disease featured ring sideroblasts, compared with about 20% of MDS patients overall.⁸

SF3B1 mutations tend to predict a more favorable course, which is important for treatment planning. In the ring sideroblast subtype, abnormalities in how mitochondria handle iron appear to tip the balance toward cell death, contributing to the anemia.³ Other chromosomal abnormalities, like deletion of part of chromosome 5, define distinct subtypes with their own treatment implications.

What Causes MDS in the First Place

For most patients, the triggering event is unknown. The mutations accumulate over a lifetime, and aging itself is the single biggest risk factor. But in a meaningful minority of cases, MDS arises as a consequence of prior cancer treatment. Chemotherapy drugs, radiation therapy, or both can damage marrow stem cells, and years later a therapy-related form of MDS emerges. One study identified 281 patients with MDS who had received prior chemotherapy or radiotherapy for an earlier cancer.⁹ Even radioactive iodine treatment for thyroid cancer has been linked to subsequent MDS, with a median delay of roughly six and a half years between treatment and diagnosis.¹⁰

Therapy-related MDS tends to carry a worse prognosis than the form that arises on its own, partly because it more often involves complex chromosomal abnormalities and higher blast counts. In transplant series, patients with therapy-related disease who had refractory anemia or refractory anemia with excess blasts made up a substantial share of cases referred for stem cell transplant.¹¹ Environmental exposures to chemicals like benzene and heavy metals are also recognized risk factors, though pinpointing a specific cause in any one patient is usually impossible.

Symptoms and Daily Life

Fatigue is the dominant symptom and the one that most affects day-to-day function. This is not ordinary tiredness; patients with MDS-related anemia describe a persistent, heavy exhaustion that interferes with relationships, work, and basic activities. In a study of patients with MDS, aplastic anemia, and related conditions, the strategies rated most helpful for managing fatigue were conserving energy, physical activity, and napping, with about 86% of respondents finding energy conservation helpful.¹²

Beyond fatigue, patients commonly experience shortness of breath, dizziness, and pallor. For those who depend on regular blood transfusions, quality of life tends to fluctuate in a sawtooth pattern. Symptom scores improve measurably in the week following a transfusion, with shortness of breath, fatigue, and weakness all getting significantly better. But those gains fade as hemoglobin levels drop again before the next transfusion.¹³ If other blood cell lines are also low, as they often are in MDS, patients may deal with recurrent infections from low white blood cells or bruising and bleeding from low platelets.

How Refractory Anemia Is Classified and Risk-Stratified

The way refractory anemia is categorized has evolved considerably. In 1982, a group of French, American, and British pathologists introduced the first widely used classification, which divided MDS into subtypes like refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess blasts. The World Health Organization later refined this system, first in 2001 and again in 2008, incorporating newer biological and clinical data to improve its ability to predict how a patient’s disease would behave.¹⁴ More recent revisions have continued this trend, moving increasingly toward molecular and genetic markers as defining features.

Once a subtype is established, risk stratification determines treatment intensity. The Revised International Prognostic Scoring System (IPSS-R), developed from data on over 7,000 patients, uses bone marrow chromosome patterns, the percentage of immature blast cells in the marrow, and the severity of low blood counts to sort patients into five risk categories rather than the original four. This finer grading helps doctors and patients decide between watchful waiting, supportive care, drug therapy, or transplant.¹⁵

Managing Lower-Risk Disease

For patients in the lower-risk categories, the primary goal is improving blood counts and quality of life rather than curing the disease outright. The first-line approach for anemia is often erythropoiesis-stimulating agents (ESAs), synthetic versions of the hormone that tells the marrow to make red blood cells. ESAs work by counteracting the excessive apoptosis of red blood cell precursors, and they produce a meaningful response in roughly 40 to 50% of lower-risk patients, with responses lasting a median of about two years.¹⁶ Even in patients who are not yet transfusion-dependent, ESAs can significantly delay the point at which regular transfusions become necessary.¹⁷

When ESAs stop working or are unlikely to help, newer agents have expanded the toolkit. Luspatercept is a drug specifically designed for patients with ring sideroblasts. It works by blocking a signaling pathway that suppresses red blood cell maturation. In a randomized trial, about 38% of patients receiving luspatercept achieved transfusion independence for at least eight weeks, compared with 13% on placebo.¹⁸ This was a meaningful advance for a group that previously had few options after ESA failure.¹⁹

Patients whose MDS involves a deletion on chromosome 5q have their own targeted therapy. Lenalidomide, an immunomodulatory drug, produces dramatic responses in this subgroup. In a pivotal trial of 148 patients with del(5q) MDS, 67% became completely transfusion-independent, with a rapid median time to response of under five weeks. The median hemoglobin rose by over 5 grams per deciliter, and many patients achieved cytogenetic remission, meaning the abnormal chromosome clone became undetectable.²⁰ Lenalidomide received FDA approval for this indication and remains a cornerstone of treatment for del(5q) disease.²¹

Managing Higher-Risk Disease

When the marrow contains a higher percentage of blast cells, the disease behaves more aggressively and carries a real risk of transforming into acute myeloid leukemia. The standard drug treatment for higher-risk MDS involves hypomethylating agents (HMAs), primarily azacitidine and decitabine. These drugs work by reversing abnormal chemical modifications on DNA that silence tumor-suppressor genes. Studies comparing the two agents in patients with refractory anemia with excess blasts have found them broadly comparable. In one multicenter analysis, overall response rates were around 49% for azacitidine and 65% for decitabine, with no statistically significant difference in overall survival (roughly 20 months for azacitidine and 17 for decitabine).²² A separate retrospective study in Chinese patients confirmed similar efficacy between the two drugs.²³ Completing at least four cycles of HMA treatment appears to be an important factor in achieving a benefit.

When higher-risk MDS does progress to acute leukemia, the outlook is influenced more by the underlying chromosome abnormalities than by what the disease was called before progression. A large study treating patients with AML-type chemotherapy found that a prior diagnosis of refractory anemia with excess blasts did not independently predict worse outcomes once cytogenetics and other characteristics were accounted for.²⁴

Stem Cell Transplant as a Potential Cure

Allogeneic stem cell transplant, where a patient receives marrow or blood stem cells from a donor, is the only treatment with true curative potential for refractory anemia and MDS more broadly. In a study of patients with refractory anemia who underwent transplant, four-year overall survival was about 52%, and outcomes were similar regardless of whether the donor was a matched sibling or a matched unrelated volunteer.²⁵

Transplant is not offered to everyone. The procedure carries substantial risks, including graft-versus-host disease and treatment-related death. Older age and waiting more than twelve months from diagnosis were both associated with worse survival in transplant recipients. On the positive side, outcomes have improved in more recent years due to refinements in conditioning regimens and supportive care, allowing transplant to be considered for patients older than 50. Reduced-intensity conditioning, which uses lower doses of chemotherapy before transplant, achieved similar survival despite a higher relapse rate, making it a viable option for patients who could not tolerate full-intensity preparation.²⁵

The Problem of Iron Overload

Patients who depend on regular red blood cell transfusions face a secondary threat that has nothing to do with their marrow disease: iron overload. Each unit of transfused blood delivers a dose of iron that the body has no efficient way to excrete. Over months and years, iron accumulates in the liver, heart, and endocrine glands, causing progressive organ damage. In one study of patients with refractory chronic anemia, ferritin levels climbed to between roughly 1,800 and 5,700 ng/mL, and patients whose ferritin exceeded 3,500 showed skin discoloration, liver dysfunction, and hormonal problems, with most of that group eventually dying.²⁶

Iron chelation therapy, using drugs that bind excess iron for removal through urine or stool, is recommended for transfusion-dependent patients whose ferritin levels rise above 1,000 ng/mL and who have received a substantial volume of transfused blood.²⁷ In practice, chelation can be challenging. The same study of refractory anemia patients found that ferritin levels did not decrease significantly in transfusion-dependent patients who received one to two months of chelation, underscoring the need for sustained, long-term treatment rather than short courses.²⁶ This is one reason why treatments that reduce or eliminate the need for transfusions, like ESAs and luspatercept, have value beyond simply raising hemoglobin: they can slow or prevent iron accumulation.

Newer Agents and Combination Strategies

The treatment landscape is shifting. Imetelstat, a telomerase inhibitor, was recently approved for lower-risk MDS based on a randomized trial showing that about 40% of patients achieved transfusion independence for eight or more weeks, compared with 15% on placebo.²⁸ It offers a new option for patients who have failed or are ineligible for ESAs.

For higher-risk disease, immune checkpoint inhibitors have been tested but so far have not produced definitive results, highlighting the need for better patient selection and combination strategies.²⁹ Investigational agents like pevonedistat, magrolimab, and sabatolimab are in various stages of clinical testing for higher-risk patients.

Perhaps the most interesting frontier involves drug combinations that attack anemia through complementary mechanisms. Pairing luspatercept with ESAs, for instance, could simultaneously promote red blood cell maturation and suppress excess apoptosis. Early-stage work is also exploring whether a class of diabetes drugs, SGLT-2 inhibitors, might have unexpected erythropoietic effects that could be harnessed for MDS-associated anemia.³⁰ Whether these combinations ultimately improve survival or merely transfusion burden remains to be seen in ongoing trials, but the pace of progress is faster now than it was even five years ago.